

# Product datasheet for TL319299V

# OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

## GPIHBP1 Human shRNA Lentiviral Particle (Locus ID 338328)

### **Product data:**

**Product Type:** shRNA Lentiviral Particles

Locus ID: 338328

**Synonyms:** GPI-HBP1; HYPL1D

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: GPIHBP1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

**RefSeq:** NM\_001301772, NM\_178172, NM\_178172.1, NM\_178172.2, NM\_178172.3, NM\_178172.4, NM\_178172.5,

NM\_001301772.1, BC035810, BC063857, NM\_001301772.2

UniProt ID: Q8IV16

Summary: This gene encodes a capillary endothelial cell protein that facilitates the lipolytic processing of

triglyceride-rich lipoproteins. The encoded protein is a glycosylphosphatidylinositol-anchored protein that is a member of the lymphocyte antigen 6 (Ly6) family. This protein plays a major role in transporting lipoprotein lipase (LPL) from the subendothelial spaces to the capillary lumen. Mutations in this gene are the cause of hyperlipoproteinemia, type 1D. Alternate

splicing results in multiple transcript variants. [provided by RefSeq, Sep 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

> For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).